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Abstract
Babesia microti is a tick born, intraerythrocytic parasite that is endemic to many North
American regions. B. microti infection causes a disease called babesiosis, a disease whose
clinical manifestation causes a wide range of symptoms, from asymptomatic infection to
fulminant disease and possible death. Transfusion transmitted babesiosis is becoming an
increasing concern as B. microti prevalence continues to grow and donor screening methods are
ineffective. Transfusion transmitted babesiosis can be extremely dangerous, with as many as one
in five cases resulting in death.
Babesia microti secreted antigen (BmSA1) is an immunogen and reliable biomarker for
B. microti infection. The aim of this work is to generate a recombinant BmSA1 protein using a
trademarked Pichia pastoris expression system called “PichiaPink™”, for use in the
development in an antigen specific ELISA as a protein standard. We hypothesize that expression
of recombinant BmSA1 in a eukaryotic yeast system will better preserve the native confirmation
and antibody recognition that might have been lost during expression in a prokaryotic expression
system. We also use bioinformatics to assess the conservation of homology of the BmSA1
protein between all B. microti strain genomes published in piroplasmaDB.com.
During this work PichiaPink™ yeast strains were successfully cloned with secretion
vectors containing the bmsa1 gene. Probing culture supernatants by Western Blot analysis with
hybridoma produced monoclonal antibodies was able to detect the rBmSA1 protein in culture
supernatants, but the antibodies also recognize proteins other than rBmSA1 in the culture
supernatant as well. Last, bioinformatics analysis of the BmSA1 protein, together with other
species of the BMN family of proteins showed great conservation of the BmSA1 protein across
viii

all strains published in the piroplasmaDB.com database, suggesting the BmSA1 protein will be a
reliable biomarker as the target of an antigen specific ELISA, as it does not appear to be subject
to genetic variation across strain.
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Introduction
Background:
Babesia ssp. are intraerythrocytic parasitic protozoa that infect a wide range of
mammalian hosts. These protozoa belong to the phylum Apicomplexa, the same as
pathogenic Plasmodium, Toxoplasma, and Cryptosporidium (Vannier & Krause, 2012;
Krause, 2019). Babesia is responsible for causing babesiosis, a disease first described in
cattle by a Hungarian pathologist named Viktor Babes in 1888 (Laha et al., 2015). The first
recorded case of human babesiosis was in 1957 (Skrabalo & Deanovic, 1957).
Babesia Epidemiology:
Babesia ssp. responsible for causing human disease are found sporadically
throughout the globe, and are endemic to the North American Northeast and Midwest
regions (Carpi et al., 2016). Several different species are capable of causing human
babesiosis, including B. microti, B. duncani, B. divergens and B. crassa (Yu et al., 2020).
B. microti is the most common cause of babesiosis in the United States (White et al.,
1998). Since 2011 there has been over 20,000 cases of babesiosis reported in the United
States alone (Yang et al., 2021). B, microti infection in the US is most commonly reported
from late spring to early autumn, when the Ixodes tick vector is most active (Krause,
2019). Recent years have seen a rapid increase in case incidence in the United States.
Warming climates expanding the geographic regions inhabitable by Ixodes ticks and
increasing white tail deer populations are likely contributing factors to the increased
incidence of babesiosis (Martínez-García et al., 2021; Spielman et al., 1985). Babesiosis is
growing in prevalence in regions outside of North America as well. One study conducted
in Beijing found that 12% of small mammals screened in the study were infected with B.

microti (Wei et al., 2020). While rare, babesiosis is present in parts of Europe as well,
where B. divergens and B. venatorum are the dominant species (Gray et al., 2010). Coinfection of babesiosis with Borrelia burgdorferi, the causative agent of Lyme disease is
common and likely underreported because the causative agents of the two diseases are
transmitted by the same Ixodes tick vector, and these diseases display similar symptoms
(Curcio et al., 2016). Tick surveillance studies are now revealing that both Babesia ssp.
and Borrelia burgdorferi can inhabit in a single tick together and infect humans during the
same tick bite transmission event (Milholland et al., 2021).
Babesia Lifecycle and Transmission:
Beginning from the point of vector transmission, Babesia enters a vertebrate host as
a sporozoite through the saliva of a tick while it is taking a blood meal. The sporozoite
travels through the blood stream until it invades host red blood cells (RBCs) (MartínezGarcía et al., 2021). Once inside the RBC, the sporozoite develops into a trophozoite.
Trophozoites undergo asexual binary fission in the RBC forming two (or more, depending
on the species) merozoites (Jalovecka et al., 2018; Milholland et al., 2021). Once formed
merozoites will eventually lyse the RBC and enter the blood stream, where they go on to
infect new RBCs (Chauvin et al., 2009). This merozoite lysis from RBCs is responsible for
many of the disease symptoms, including hemolytic anemia, jaundice, and renal
deficiencies (Krause, 2019). Some merozoites will differentiate into pre-gametocytes
inside the RBC. Pre-gametocytes lyse their resident RBCs and develop into extracellular
gametocytes. It is the gametocytes that are capable of surviving ingestion by a new tick
(Chauvin et al., 2009).
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Once ingested by a new Ixodes tick when it takes a blood meal from an infected
host, gametocytes mature into gametes, also known as “ray-bodies”. Ray-bodies undergo
sexual reproduction by fission and develop into ookinetes. Ookinetes then penetrate cells
of the tick’s gut where they undergo meiotic divisions, developing into kinetes (Milholland
et al., 2021). Kinetes disseminate through the tissues of the tick until reaching their
salivary glands, where they will differentiate into sporoblasts capable of infecting the next
vertebrate that is bitten by the tick, repeating the Babesia life cycle (Jalovecka et al., 2018;
Mehlhorn & Schein, 1985).
Human Babesiosis Clinical Manifestation:
Many babesiosis infections in immune competent individuals are asymptomatic. In
some endemic areas seroprevalence studies have found as many as one in five residents are
asymptomatically seropositive, meaning that they have antibodies to B. microti indicative
of a current of past infection. (Diuk-Wasser et al., 2014). Common clinical presentations of
babesiosis typically occur between 1 to 4 weeks after a tick bite and transmission of the
parasite. Transfusion-transmitted infections typically have an incubation period of 1 to 9
weeks (Vannier et al., 2015), and severe disease is common with transfusion-transmitted
Babesia. Babesiosis presents with a range of clinical symptoms, but most common are
fever and fatigue. Other symptoms include: chills, headache, nausea, myalgia, and
arthralgia (White et al., 1998). Babesiosis can occasionally cause splenomegaly and
hepatomegaly. Severe/fatal disease is rare in immune-competent individuals, but more
common in immunocompromised and elderly individuals (Hatcher et al., 2001). Asplenic
patients are more likely to develop the severe disease than others (Dumic et al., 2020).
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Severe babesiosis may result in ARDS, pulmonary edema, CHF, renal failure, splenic
rupture, and possibly death (Hatcher et al., 2001).
Babesiosis Treatment:
Primary treatment regimens for any patient diagnosed with babesiosis is a 7–10-day
course of combination atovaquone and azithromycin therapy. For patients unable to take
either of these medications due to allergies or other reasons, or for patients for whom this
therapy is not effective, a clindamycin and quinone combination is the recommended
second line of treatment. Treatment is often extended past 10 days in immunocompromised
patients (Krause et al., 2021). Drug treatment is not parasiticidal and in the case of high
parasitemia, multiple red blood cell exchanges may be required to decrease parasite
burden. While most studies show that the clindamycin and quinone combination therapy is
equally as effective as the atovaquone and azithromycin combination therapy, the
clindamycin and quinone combination regimen has shown to produce adverse side effects
at a much higher rate (Krause et al., 2000) (Vannier et al., 2015). The most commonly
reported side effects of the clindamycin and quinone combination therapy are: tinnitus,
diarrhea, and temporary hearing loss (Krause et al., 2000).
Transfusion-transmitted infection:
Babesiosis is one of the most frequently acquired transfusion-transmitted diseases
in the United States and one of the more common causes of transfusion-transmitted
infection fatalities. (Moritz et al., 2016). The first case of transfusion-transmitted
babesiosis was in 1994 in Washington State (Herwaldt et al., 1997). As many as 1 in 5
transfusion-transmitted Babesia infections result in death (Bloch et al., 2019). Babesia
infections create unique problems to screening in blood banks. Health history screening of
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donors is rarely effective due to the high asymptomatic rate of babesiosis, growing
prevalence, and the fact that many people have never heard of babesiosis (Leiby, 2011).
Studies have shown that B. microti can survive in blood samples stored at 4°C for up to 21
days post collection (Eberhard et al., 1995). Almost all confirmed cases of transfusiontransmitted babesiosis are caused by B. microti (Leiby, 2011), with a few rare reports of
transfusion-transmitted babesiosis being caused by the babesia species B. duncani
(Herwaldt et al., 1997).
Diagnosis of babesiosis:
Diagnosis of babesiosis is currently confirmed by a thin-layer blood smear with
positive qPCR confirmation (Krause et al., 2021). These methods are adequate for
diagnosing patient samples, but are ergonomically unrealistic strategies for screening large
volumes of blood donation samples in a cost-effective manner as required by Blood Banks
(Simon et al., 2014). There is currently only one approved molecular screening tool for the
detection of babesiosis infected blood samples used to prevent TTB called “Procleix
Babesia Assay” (from Grifols Diagnostic Solutions). Procleix is a nucleic acid testing
(NAT) assay that targets the 18s rRNA transcripts of B. microti, B. divergens, B. duncani,
and B. venatorum species (Tonnetti et al., 2020). The assay runs on the Procleix Panther
system, a fully automated platform utilizing Nucleic Acid Testing (NAT) for blood
screening. The FDA approval recognized a successful multi-center clinical trial conducted
under an Investigational New Drug (IND) study at the American Red Cross, Creative
Testing Solutions, and Rhode Island Blood Center (an affiliate of the New York Blood
Center, Inc.) in select areas of the U.S., blood samples must be shipped to the company for
screening.
5

The issue with NAT assays like Procleix and qPCR for screening blood donation
samples is that these types of transcription-mediated assays are cost-ineffective. Studies
have shown that serological assays would be the most economically sensible method for
screening blood donations by blood banks (Simon et al., 2014). However, indirect
immunologic serology assays like indirect enzyme-linked immunosorbent assay (ELISA)
are disadvantageous because high antibody titers are not indicative of active infection,
resulting in potentially high false positive-rates (Alvarez et al., 2019). The development of
a direct antigen capture ELISA (“sandwich ELISA”) would eliminate the complication of
relying on antibody titers while still remaining an economically reasonable option.
However, in order to develop such an antigen-specific ELISA for use by Blood Banks to
prevent TTB, immunogenic Babesia antigens need to be identified, synthesized and
antigen-specific monoclonal antibodies need to be developed.
BmSA1:
Babesia microti secreted antigen 1 (BmSA1) is a GPI-linked secreted B. microti
protein (Cornillot et al., 2016). BmSA1 binds to host RBCs and has been implicated in
facilitating RBC invasion by merozoites (Li et al., 2020). This protein belongs to the BMN
family of babesia proteins, with the most homology to the BMN1-9 protein (Luo et al.,
2011). BmSA1 was identified in the Gray Strain of B. microti. The protein was identified
as BmGPI12 in other strains of B. microti, and the two names (BmSA1 and BmGPI12) are
now used synonymously (Cornillot et al., 2016). BmSA1 is a 33-kDa protein with a
cleavable N-terminus secretion signal sequence (Luo et al., 2011). This protein is an
immunodominant B. microti antigen. (Thekkiniath et al., 2018).
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BmSA1 as a Biomarker and Immunogen:
Research using BmSA1 as the target of antigen capture assays has proven sensitive
and effective. One study by the National Research Center for Protozoan Diseases at the
Obihiro University of Agriculture and Veterinary Medicine was able to identify B. microti
infection in hamsters as early as two days post-infection using a BmSA1 antigen capture
ELISA (Luo et al., 2012). Another study out of Yale School of Medicine was able to
design a BmSA1 antigen capture ELISA that was more sensitive than real-time qPCR
diagnosis (Thekkiniath et al., 2018). Furthermore, in vitro studies have shown that antiBmSA1 antiserum will significantly inhibit the growth of parasites in RBC tissue cultures,
indicating the protein as a potential therapeutic target and vaccine candidate (Li et al.,
2020).
Research using Expression of rBmSA1
BmSA1 is quickly becoming an “antigen of choice” for designing diagnostic
assays; particularly serological assays. In China, some seroprevalence studies are already
being conducted using antigen-capture ELISA assays targeting BmSA1 in blood donor
pools (Lin et al., 2019). The growing awareness of BmSA1 as a potential key virulence
factor, immunogen for diagnostics, and biomarker for B. microti infection has generated a
clear need for a reliable method of synthesizing rBmSA1 protein that resembles that of the
“wild-type” protein expressed by B. microti.
To date, most research using rBmSA1 for immune studies have used Escherichia
coli bacteria for protein expression (Luo et al., 2011) (Cornillot et al., 2016; Cai et al.,
2018; Thekkiniath et al., 2018; Lin et al., 2019; Li et al., 2020; Verma et al., 2020).
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However, B. microti is a eukaryotic pathogen and E. coli is unable to ensure proper posttranslational processing of BmSA1. More recent studies have used human cell line models
for expression, like human embryonic kidney (HEK) cells (Elton et al., 2019). Human cell
lines expression models are not ideal for expressing B. microti proteins either, as they
might actually hyperglycosylated rBmSA1 proteins as they contain more glycosylase
enzymes than Apicomplexan cells (Lombard, 2016). Also, most human cell lines are poor
venues for large-scale production of heterologous protein. In a study by Elton et. al.,
researchers resorted to altering the amino acid sequence inside of an N-linked
glycosylation consensus site of the HEK expressed rBmSA1 because Babesia ssp. lack the
enzyme that recognizes this specific glycosylation motif (Lombard, 2016). Altering amino
acid sequences of a protein could also alter the immunogenicity of an antigen like BmSA1.
Pichia pastoris and PichiaPink™ Expression Systems:
The use of Pichia pastoris yeast models for the expression of recombinant proteins
has many advantages over other biological expression systems, particularly for
heterologous expression of eukaryotic proteins. Pichia pastoris ca express large quantities
of recombinant heterologous proteins and can be used in the industrial setting (Buckholz &
Gleeson, 1991). Pichia pastoris are methylotrophic yeast capable of metabolizing methanol
as their sole carbon source (Faber et al., 1995). The ability to metabolize methanol comes
from their expression of alcohol oxidase enzymes. Alcohol oxidase metabolizes methanol
to formaldehyde and peroxide. The Pichia pastoris genomes contain two alcohol oxidase
genes, AOX1 and AOX2. AOX1 is responsible for the majority of alcohol oxidase
expression in these cells. The significance of the alcohol oxidase gene in the expression of
recombinant protein is that the AOX1 gene is tightly controlled under the regulation of its
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own methanol-induced promoter. Using genetic cloning mechanisms, genes of interest can
be cloned downstream of this promoter to enable heterologous protein expression through
the induction of alcohol oxidase expression. Alcohol oxidase binds to oxygen with poor
affinity and Pichia pastoris compensates for this by expressing alcohol oxidase at high
levels. As such, any genes that are coupled to this expression will be expressed at high
levels as well (Invitrogen, 2014).
Pichia pastoris expression models have another key advantage, specifically over
other commonly used prokaryotic expression models like E. coli. Prokaryotes lack
membrane-bound organelles, and as a result, a recombinant protein expressed by these
cells will lack any posttranslational modifications that occur in the endoplasmic reticulum,
Golgi apparatus, secretory pathway of eukaryotic cells (Buckholz & Gleeson, 1991).
Pichia pastoris post-translational modifications resemble those of higher eukaryotes,
especially glycoprotein modifications. This is important when using recombinant proteins
in studies that require bioactive proteins or rely on antibody recognition, like ELISA
development. Studies have shown that glycosylated immunogens have their
immunogenicity better conserved when expressed in eukaryotic models versus prokaryotic
models (Bagno et al., 2020).
The PichiaPink™ Expression System is a trademarked Pichia pastoris expression
model that incorporates 4 proprietary yeast strains and unique cloning vectors to facilitate
the generation of recombinant proteins. The yeast strains are designed to express varying
levels of protease knockouts to prevent the degradation of a recombinantly expressed
protein. Strain 1 is a “wild-type” expressing protease strain that has no protease gene
knockouts. Strain 2 is a Proteinase A gene pep4 knockout. Strain 3 contains a proteinase B
9

gene prb1 knockout. Strain 4 is both a pep4 and prb1 knockout. The cloning vectors are
constructed with genes for antibiotic resistance, adenine complementation for selection
(Figure 1), and cloning sites for insertion of genes of interest, all designed to facilitate the
successful cloning of PichiaPink™ strains. The PichiaPink™ Expression System also
includes vectors that allow heterologous proteins to be secreted resulting in improvements
of purification of the heterologous recombinant proteins (Invitrogen, 2014).
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Figure 1: This image is a sample image from ThermoFisher.com that shows the
appearance of PichiaPink™ colonies growing on PAD selection agar following
electroporation. The red colonies contain low vector insert copy numbers, and the white
colonies contain high vector insert copy numbers –
(https://www.thermofisher.com/order/catalog/product/A11156#/A11156) (Invitrogen,
2014).
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Monoclonal Antibodies
An antibody library was constructed for the generation of monoclonal antibodies by
hybridoma cells against B. microti, Gray strain ATCC-30221 cultured in vivo in BALB/c
mice. These antibodies were previously validated against rBmSA1 expressed in E. coli.
The two antibodies used in this study, RD167 and RD261 both recognize E. coli expressed
rBmSA1 by Western Blot analysis. The E. coli expressed rBmSA1 for validation was Histagged and purified by a nickel column prior to Western Blot analysis. In the unpurified E.
coli lysate RD167 recognizes a protein bands of higher molecular weight (100kDa and
75kDa). The antibody RD261 was never screened against the unpurified E. coli lysate, but
it did recognize a protein band of 55kDa in the purified protein sample. The investigators
suggest a possible explanation for staining of the higher molecular weight bands in the
unpurified lysate by RD167 to be the results of the Alkaline Phosphatase Goat Anti-Mouse
IgG secondary antibodies binding to endogenously expressed E. coli proteins that contain
Fab antibody binding domains. However, this hypothesis was never tested. The
investigators suggest a possible explanation for the staining of the 55kDa band by RD261
in the purified protein samples to be the presence of rBmSA1 protein aggregates. This
hypothesis has also never been tested. One of the aims of this study is to generate rBmSA1
using a Pichia pastoris expression system to see if these antibodies still recognize
molecular weight bands other than those consistent with rBmSA1.
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Materials and Methods
Primer Design
All primers were ordered through IDT Technologies. Primer sequences used in the study
are listed in Table 1
bmsa1 and bmn1-21 Gene Amplification:
B. microti Gray Strain ATCC 30221 was used as the source of template DNA for
PCR amplification of B. microti sequences from parasites. DNA purification from blood
tissue samples was performed using Qiagen® DNeasy blood and tissue kit, as per the
manufacture’s protocol. 400µl of blood from B. microti infected mice was frozen upon
isolation at -80°C and used for isolation/purification of parasite DNA. The bmsa1 and
bmn1-21 genes were amplified from the purified template DNA by PCR, using the primers
for PCR amplification underlined in (Table 1), using Phusion® High-Fidelity PCR Master
Mix. Unique primers were designed to create adaptors for 5’ end of the bmsa1 gene,
including synthesis of a phosphorylated 5’ end, and a 3’KpnI restriction site adapter at the
end of the bmsa1 gene. For bmn1-21, a 5’ adaptor with a MlyI restriction site and 3’
adaptor to include a 3’KpnI restriction site adapter on the amplified bmn1-21 gene.
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PRIMER DESCRIPTION
BMSA1 FORWARD 5’
PHOSPHORYLATED PRIMER FOR
PCR AMPLIFICATION

PRIMER SEQUENCE
5’-5Phos/GCT-GGT-GGT-AGT-GGTGGT-AAT-G-3’

BMSA1 REVERSE PRIMER WITH
KPNI RESTRICTION SITE FOR PCR
AMPLIFICATION

5’AAA-GGT-ACC-TTA-GAA-TAGAAA-CAT-AGC-GAC-CGA-G-3’

BMN1-21 FORWARD PRIMER WITH
MLYI RESTRICTION SITE FOR PCR
AMPLIFICATION

5’-AAA-GAG-TCA-AAA-AGG-AAATGG-TGA-TGT-TAA-TCA-ATA-TT-3’

BMN1-21 REVERSE PRIMER WITH
KPNI RESTRICTION SITE FOR PCR
AMPLIFICATION

5’-AAA-GGT-ACC-TTA-ATT-TAGATT-TAA-TAT-TAA-TGC-A-3’

VECTOR-SPECIFIC ALPHASECRETION SIGNAL SEQUENCE
FORWARD PRIMER FOR
SEQUENCING CLONES

5’-ACT-ATT-GCC-AGC-ATT-GCTGCT-AAA-G-3’

VECTOR-SPECIFIC C-GAMMA-C1
TERMINATOR SEQUENCE
REVERSE PRIMER FOR
SEQUENCING CLONES

5’-TTA-CAT-GAT-ATC-GAC-AAAGGA-AAA-G-3’

BMSA1 INTERIOR SEQUENCE
FORWARD PRIMER FOR
SEQUENCING CLONES 3’
JUNCTION

5’-CCT-CCG-ATA-TCT-CCG-CTATTA-AG-3’

BMSA1 INTERIOR SEQUENCE
REVERSE PRIMER FOR
SEQUENCING CLONES 5’
JUNCTION

5’-CAT-CCA-CTT-CAG-CAG-CAGTAT-C-3’

Table 1: A table of all PCR primers used for this research. All primers were synthesized
through Integrated DNA Technologies ™
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pPinkα-HC Secretion Vector Generation:
The pPinkα-HC secretion vector was obtained from Fisher Scientific as part of the
PichiaPink™ Secretion Vector Kit. The vector was used to transform Stellar Chemically
Component™ E. coli and transformed bacterium was plated overnight on Luria-Bertani
(LB) plus ampicillin agar plates (Table 2). Bacterial colonies were selected and evaluated
by PCR and restriction enzyme digestion for the presence of the pPinkα-HC secretion
vector.
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Medium Name
LB Broth + Carbenicillin
LB Agar + Carbenicillin
YPD agar
YPD broth
YPDS broth
BMGY medium (Buffered Glycerolcomplex Medium)

BMMY medium (Buffered Methanolcomplex Medium)

Composition
1:1,000 (LB broth:Carbenicillin)
1:1,000 (LB agar:Carbenicillin)
2% agar, 2% peptone, 2% yeast extract, 2%
dextrose
2% peptone, 2% yeast extract, 2% dextrose
2% peptone, 2% yeast extract, 2%
dextrose, sorbitol 1M
1% yeast extract, 2% peptone, 100mM
potassium phosphate pH 6.0, 1.34% yeast
nitrogen base, 0.00004% biotin, 1%
glycerol
1% yeast extract, 2% peptone, 100mM
potassium phosphate pH 6.0, 1.34% yeast
nitrogen base, 0.00004% biotin, 0.5%
methanol

PAD agar (Pichia Adenine Dropout)
PichiaPink™ Media Kit

Table 2: A comprehensive table of all media used for this research, with respective media
compositions.
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Transformed E. coli with confirmed expression of the pPinkα-HC secretion vector
were prepared in glycerol stock and stored at -80°C prior to use. For experiments, the
pPinkα-HC secretion vector containing E. coli was propagated in LB broth containing
100µl (1:1,000) of carbenicillin and cultured for 24 hours on a shaker at 37°C. Cultures
were then harvested and subject to plasmid template purification using Qiagen™ Spin
Midiprep Kit for Plasmid DNA purification, per the manufacture’s protocol.
To ensure the identity and integrity of the pPinkα-HC vector plasmids were correct
and intact, restriction digest to check for accurate restriction fragment sizes was conducted
on a 20µl aliquot of the purified template yield from the Midiprep purified plasmids
template. The restriction digest reaction included cleavage with HindIII, NotI, and XbaI
restriction enzymes in separate reactions. Restriction enzymes were purchased through
New England Bio Labs ™, and 20µl reactions were conducted at 37°C overnight, per the
manufacture’s protocol. The size of the vector before cleavage with restriction digest
enzymes was 8000 base pairs. Restriction digestion with HindIII cut the plasmid twice,
generating approximately 3000 base pair and 5000 base pair fragments. Restriction
digestion XbaI also cut the plasmid twice, resulting in an approximately 2000 base pair
fragment and a 6000 base pair fragment. Restriction digestion with NotI cut the plasmid
only once, so the expected fragment size of DNA generated from that reaction was 8000
base pairs. All restriction digestion reactions resulted in the generation of appropriately
expected restriction fragment sizes when observed by horizontal gel electrophoresis.
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Preparing bmsa1, bmn1-21 and pPinkα-HC for Cloning:
To prepare the bmsa1 gene for cloning into the pPinkα-HC secretion vector
plasmid, the amplified bmsa1 gene with its adaptor sequence was digested with KpnI in a
20µl reaction in order to cleave its 3’ KpnI site adaptor needed for cloning the gene into the
PichiaPink Vector. The restriction enzyme digest was conducted at 37°C for 2 hours, per
manufacture’s protocol. Since the 5’ end of the gene was synthesized with a
phosphorylated end, no preparation was necessary to make it compatible with the ligase
reaction for cloning. To prepare the bmn1-21 gene for cloning into the pPinkα-HC
secretion vector plasmid, a 20µl restriction digestion reaction was set up using KpnI and
MlyI to cleave the 3’KpnI site adapter and 5’MlyI site adaptors synthesized onto the gene
during amplification. This reaction was also conducted at 37°C for 2 hours, as per the
manufacture’s protocol. To prepare the pPinkα-HC secretion vector plasmid for cloning, a
20µl restriction digest reaction was set up using KpnI and StuI to cleave the 5’ StuI site and
3’ KpnI sites of the vector for insertion of GOIs. Restriction enzymes StuI, KpnI and MlyI
were purchased from New England Biolabs ®. These restriction reactions were conducted
at 37°C for 2 hours, per the manufacture’s protocol. These cleavages generated
complementary ligation sites for proper placement and orientation of GOIs during the
cloning ligation reaction. The cleaved plasmid product was treated with quick CIP from
New England Biolabs ® to prevent relegation of gene fragment ends prior to insertion of
GOIs. Quick CIP treatment was conducted at room temperature for 10 minutes, as per
manufacture’s protocol.
Ligation of Plasmid/GOI duplex
Ligation was performed using the Quick Ligation ™ Kit from New England
Biolabs ® Inc. with Quick T4 DNA Ligase. 50ng of cleaved vector DNA was ligated to
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35ng of GOI DNA in a 5-minute ligation reaction, as per the manufacture’s protocol.
Ligation product was transformed into Stellar ™ Competent E. coli cells as per the
manufacture’s protocol. Cells were plated on LB agar + Carbenicillin plates (1:1,000
carbenicillin: LB agar) to screen for recombinants. Individual colonies were selected for
DNA purification (Figure 2). DNA isolation from transformed bacteria for subsequent
PCR amplification with vector-specific primers that spanned the GOIs insertion site was
performed using a boil preparation procedure. Colonies were suspended in 20µl of sterile
water and heated to 100° for 10 minutes. The cell suspension was then centrifuged at
16,000 x g for 5 minutes. The supernatant containing the DNA was used for PCR.
Successful insertion of the GOIs was confirmed by PCR using the “vector-specific primers
for screening recombinants” shown in the Table 1, using GoTaq® DNA Polymerase in
GoTaq® Master Mix. PCR product was run on horizontal gel electrophoresis for
confirmation of a vector size DNA band.
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Figure 2: A diagram of the experimental protocol to create heterologous bmsa1 and bmn121 in the pPinkα-HC secretion vector and for protein expression. On the top left (denoted
by the black square) is the pPinkα-HC secretion vector used for cloning.
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Preparation of PichiaPink™ Strains for Electroporation:
Four clones of PichiaPink™ yeast were used for transformation with the
PichiaPink™ secretion vector containing the GOIs. The four yeast strains differed from
one another based on the number of endogenous proteases present as each strain had
different combinations of yeast proteases that had been deleted to avoid potential protease
cleavage of the heterologous protein if necessary. Competent yeast strains were prepared
for transfection according to manufacturer’s instructions. The four yeast clones were
obtained from frozen glycerol stock and plated for isolation on YPD agar plates (Table 2).
Strains were incubated for three days at 28°C in an incubator after which individual
colonies were selected for each of the four yeast strains and inoculated in 10mL of YPD
media (Table 2) in a 250mL baffled flask. Yeast was grown in suspension on a shaking
incubator at 300rpm at 28°C for 24 hours. This starter culture was used to inoculate 100mL
of YPD media and grown to an OD600 of 0.2. This culture was grown to an OD600 of 1.3,
then yeast centrifuged at 1,500 x g for five minutes at 4°C. Yeast pellets were resuspended
in 250mL of ice-cold, sterile water. Cells were centrifuged a second time at 1,500 x g for
five minutes at 4°C then resuspended in 50mL of ice-cold, sterile water. Cells were
centrifuged a third time at 1,500 x g for five minutes at 4°C then resuspended in 10 mL of
ice-cold 1M sorbitol. Cells were centrifuged a final time at 1,500 x g for five minutes at
4°C then resuspended in 300 µl of ice-cold 1M sorbitol. Cells were kept on ice and used
the same day.
Electroporation of PichiaPink ™ :
The following electroporation protocol was used for all electroporation for the
transfection of Pichai pastoris yeast. Electrocompetent PichiaPink™ cells (80µl) were
mixed with 8µg of linearized bmsa1 plasmid. Plasmids were linearized with the restriction
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enzyme EcoNI, cutting the plasmid at position 5326bp to linearize the plasmid and to
generate a 1bp overhang. PichiaPink™ cells and Vector/GOI duplex DNA were mixed in
ice-cold 2mm cuvettes for electroporation. Cells were pulsed in a BTX Electro Cell
Manipulator ® electroporator under the following parameters: 25µF, 200Ω, 150v.
Immediately after electroporation, 1mL of ice-cold YPDS media (Table 2) was added
directly to the cuvettes by pipetting up and down, and cultures were incubated at 28°C for
2 hours inside the cuvettes. After 2 hours, cells were plated on PAD selection agar at 100µl
and 300µl volumes. Cells were incubated on PAD agar for 3 days until colonies began to
form, which were allowed to grow for one more day at which point colonies were
transferred to fresh PAD selection agar plates (Table 2) for another 3 days. Each colony
plate was used as a source to propagate yeast in suspension in order to create glycerol
stocks. Transfected yeast clones were frozen for long-term storage in 50% glycerol and
stored at -80°C.
PichiaPink™ Heterologous Protein Expression Culture:
From fresh PAD cultures, 25mL of BMGY medium (Table 2) was inoculated with
a single transfected yeast colony in 250mL baffled flasks. These cultures were allowed to
grow for 24 hours at 28°C in a shaking incubator at 280 rpm. After 24 hours, cells were
transferred to separate 50mL conical tubes and centrifuged at 1,500 x g for 5 minutes at
room temperature. The BMGY media was discarded and the pellet was resuspended in
2mL of BMMY media (Table 2). Before placing the cultures back on the incubator, caps
were replaced with sterile gauze to allow for adequate aeration of cultures. The BMMY
cultures were placed back on the shaking incubator for 24 hours at 28°C shaking at 280
rpm. After 24 hours of culture, 100µl was removed for the 0-hour time point collection
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sample. Cultures were replenished with 100µl of 40% methanol. For each time point
collected after that, 100µl of media were collected, and cultures were replenished with an
additional 100µl of 40% methanol.
Supernatant and Pellet Lysate Sample Preparation:
Each 100µl yeast sample collection was transferred into a microcentrifuge tube
where 1µl of HALT™ protease inhibitor was added to the sample to a final 1x
concentration of protease inhibitor. Samples were then centrifuged at 1,500 x g for 10
minutes. Supernatants were transferred to a new clean microcentrifuge tube and stored at 80°C prior to analysis by either vertical acrylamide electrophoresis for Coomassie staining
of proteins or for Western Blot analysis. Cell pellets from each collection were also stored
at -80°C prior to sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS PAGE)
separation of proteins for analysis by Coomassie staining or Western Blot analysis. After
yeast supernatant and pellets were collected for all time points, the supernatants were
thawed and prepared for SDS-PAGE. In preparation for SDS-PAGE, supernatants were
mixed in a 1:1 mixture ratio with Laemmli Sample Buffer and 2-Mercaptoethanol (19:1
Laemmli Sample Buffer:2-Mercaptoethanol).
Cell pellets were thawed and resuspended in a 10:1 pellet volume: Breaking Buffer
solution (50 mM sodium phosphate pH 7.4, 1mM PMSF, 1mM EDTA, 5% glycerol) .
Then, equal volumes of 0.5µm acid wash beads from VWR North American® were added
to the pellet suspension in Breaking Buffer. The bead pellet suspension mixture was
subject to vortex at max speed 8 cycles of 30 seconds on, with 30 seconds rest. After
vortexing the suspension was centrifuged for 10 minutes at 15,000 x g at 4°C. After
centrifugation, the supernatant was carefully transferred to a fresh microcentrifuge tube. As
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with the supernatant samples, in preparation for SDS-PAGE, pellet lysates were mixed in a
1:1 mixture ratio with Laemmli Sample Buffer and 2-Mercaptoethanol (19:1 Laemmli
Sample Buffer:2-Mercaptoethanol).
SDS-PAGE:
BIO-RAD Mini-PROTEAN ® 10 and 12 lane precast SDS-PAGE gels were used
for all SDS-PAGE. Gels were run in 1x Tris/Glycine/SDS loading buffer. Samples were
incubated at 100°C for 10 minutes prior to loading into gels. All wells were loaded with
10µl of BIO-RAD Precision Plus® Protein Standard ladder and 10µl of the sample unless
otherwise stated in the figure legend. Gels were run at 125v for approximately 45 minutes
until the dye front reached the bottom of the gel. These conditions were the same for gels
used in Coomassie-stain and gels used in nitrocellulose membrane transfer for Western
Blot analysis.
Coomassie Stain
Gels were fixed in fixing solution (50% methanol, 10% glacial acetic acid) for 30
minutes on a shaker set to low. Staining was done with Coomassie dye (0.1% Coomassie
Brilliant Blue R-250, 50% methanol, 10% glacial acetic acid) for 1 hour following
fixation. After 1-hour gels were destained in destaining solution (40% methanol, 10%
glacial acetic acid) until bands began to appear (approximately 20 minutes), and then
destaining continued in distilled water until gels were fully destained.
Western Blot Analysis
All protein transfers from SDS-PAGE gels to nitrocellulose membranes were done
using a BIO-RAD Trans-Blot® SD Semi-Dry Electrophoretic Transfer cell. Towbin
Transfer Buffer (25mM Tris, 192mM glycine (20% methanol), pH8.3 in dH2O) was used
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for the semi-dry transfer. The transfer was conducted for 20 minutes at 15 volts. Following
the transfer, nitrocellulose membranes were blocked in blocking buffer (TBST with 3%
bovine serum albumin) for 45 minutes. After blocking for 45 minutes the nitrocellulose
membranes were rinsed for 3 x 5 minutes in TBST (20µm Tris (pH 7.5), 150µm NaCl,
0.1% tween in 1L dH2O). After rinsing in TBST, membranes were incubated in 1:10
dilution of primary antibody in blocking buffer solution, for one hour at room temperature
or overnight at 4°C. After incubation with primary antibodies, the nitrocellulose
membranes were rinsed in TBST 3 x 5 times, then incubated in a 1:10,000 secondary
antibody: blocking buffer solution for 1 hour. Alkaline Phosphatase Goat Anti-Mouse IgG
secondary antibodies from Jackson Immunoresearch Laboratories Inc. were used for all
western blot analyses. Following the secondary antibody incubation, the nitrocellulose
membranes were rinse in TBS (no Tween) 3 x 5 times. Following the TBS rinse,
membranes were incubated in Thermo Fisher™ BCIP/NBT alkaline phosphatase substrate
for chromogenic detection of antibodies. Once bands were clear, the chromogenic
detection reaction was stopped by rinsing the membrane in dH2O.
Genomic DNA Isolation from PichiaPink™:
All genomic DNA isolation from the transfected PichiaPink™ strains was done using
Norgen Biotek Corp.® Fungi/Yeast Genomic DNA Isolation Kit, with additional
Zymolase treatment for cell wall disruption, per manufacturers protocol.
Genome Sequencing and Alignment:
All Sanger sequencing for genomic DNA was conducted by adding appropriate primers to
DNA as per GENEWIZ® instruction and then submitted to GENEWIZ® for Sanger
sequencing. Alignments for bmsa1 and bmn1-21 genes were done using the NCBI
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sequence XP_012648767.1 as a reference. All alignments were done using MUSCLE or
Clustal Omega alignment tools through SnapGene Pro® software, unless stated otherwise
in the text.
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Results
The goal of this study was to use a Pichia pastoris heterologous expression vector to
create recombinant BmSA1 and BMN1-21 (rBmSA1 and rBMN1-21) protein for use in a
pilot antigen-specific antibody capture enzyme-linked immunoassay (ELISA) that is under
development. To evaluate genetic diversity in bmsa1 and bmn1-21, both genes were
amplified by PCR with gene-specific primers from the B. microti, Gray strain obtained
from the American Type Culture Collection (ATCC-30221) and propagated in vivo in
BALB/c mice. The Gray strain of B. microti was isolated from a human patient from
Nantucket Island, MA in 1970. The amplified bmsa1 and bmn1-21 genes were sequenced
and the genomic sequences were compared by Basic Local Alignment Search Tool
(BLAST) to the genomic sequence of independent B. microti isolates that are referenced on
the PiroplasmaDB.org library/search engine, as well as the NCBI library/search engine.
Shown in Table 3 and Table 4 are the alignments of bmsa1 and bmn1-21 from the B.
microti Gray strain with the other B. microti parasite isolates sequenced to date. The bmsa1
alignments in Table 3 show an exhaustive list of cataloged genomes for B. microti species,
indicating all of the known B. microti bmsa1 genes are highly conserved with 100%
sequence homology.
The BMN1 family of proteins are thought to be members of variable surface proteins
in B. microti. The BLAST alignment of the bmn1-21 gene did identify variability between
the B. microti Gray Strain ATCC 30221 bmn1-21 gene and bmn1-21 genes from other B.
microti isolates identified and registered on piroplasmaDB.org (Query covers of 78% for
Naushon, ATCC 30222, ATCC PRA-99, and Nan_Hs_2011_N11_50 strains) (Table 4).
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bmsa1
Strain Name

Sequence ID

Score

E-

Query Identity

value Cover
B. microti strain RI

LN871598

1781

0.0

100%

100%

B. microti strain Naushon

JGUX01000084.1

1775

0.0

100%

100%

B. microti strain ATCC

JGVA01000085.1

1775

0.0

100%

100%

JGUZ01000081.1

1775

0.0

100%

100%

B. microti strain GI

JGUY0100088.1

1775

0.0

100%

100%

B. microti Greenwich Yale

JGUW01000191.1

1775

0.0

100%

100%

JGUV01000099.1

1775

0.0

100%

100%

30222
B. microti strain ATCC
PRA-99

Lab Strain 1
B. microti strain
Nan_Hs_2011_N11_50
Table 3: The BLAST alignments with the B. microti Gray Strain ATCC 30221 bmsa1
gene sequence. PiroplasmaDB.com BLAST alignment tool was used for alignments.
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bmn1-21
Strain Name

Sequence ID

Score E-

Query

value

Cover

Identity

B. microti strain RI

FO082872

1651

0.0

100%

100%

B. microti Greenwich

JGUW01000186.1 1609

0.0

100%

100%

B. microti strain Naushon

JGUX01000105.1

201

9e -51

78%

99%

B. microti strain

JGVA01000127.1

201

9e -51

78%

99%

JGUZ01000069.1

201

9e -51

78%

99%

JGUV01000066.1

201

9e -51

78%

99%

Yale
Lab Strain 1

ATCC30222
B. microti strain ATCC
PRA-99
B. microti strain
Nan_Hs_2011_N11_50
Table 4: The BLAST alignments with the B. microti Gray Strain ATCC 30221 BMN-1-21
gene sequence. PiroplasmaDB.com BLAST alignment tool was used for alignments.
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However, these variations are almost entirely silent as the translated protein products
from these genes contain 99% amino acid sequence identity to the Gray Strain ATCC
30221 BMN1-21 protein.
The BmSA1 protein is closely related to the BMN1 family of proteins, but it is
divergent from a BMN1 protein subtype called BMN1-9 that shares little homology to the
larger BMN1 family of proteins that BMN1-21 belongs to. The B. microti Gray Strain
ATCC 30221 bmn1-21 gene and bmsa1 gene only share 50% sequence identity to each
other (Figure 3). Their translated protein products are even more dissimilar. The BMN1-21
translated protein shares only 23% sequence identity to the BmSA1 translated protein, with
42% sequence similarity (Figure 4). Amino acids are considered similar if they are both
either: non-polar, polar neutral charge, acidic, or basic amino acids.
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Figure 3: Local alignment of B. microti Gray Strain ATCC 30221 bmn1-21 gene and
bmsa1 gene. The two sequences share 50.09% sequence identity. Local alignment was
performed using the Smith-Waterman algorithm.
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Figure 4: Local alignment of B. microti Gray Strain ATCC 20331 BMN1-21 protein and
BmSA1 protein. The two sequences share 23.15% sequence identity, and 42.14%
similarity. Local alignment was performed using the Smith-Waterman algorithm.
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The Gray Strain ATCC 30221 bmsa1 gene is much more homologous to the bmn1-9
gene identified in B. microti strain MN1. With the exception of the first 27 base pairs at the
beginning of the bmsa1 gene inside of the bmsa1 secretion signal sequence that is not
present in the bmn1-9 gene, these two genes share 99% sequence identity to each other
(Figure 5a). These sequences differ from each other by one base pair in the middle of the
gene, where an adenine in the BMN1-9 gene is replaced with a guanine in the BmSA1 gene.
Their translated protein products share 99% sequence identity and 100% sequence
similarity, as the only variation in their protein sequences is a lysine in the BMN1-9 amino
acid sequence that is replaced with an arginine in the BmSA1 amino acid sequence (Figure
5b). The BLAST alignment of the bmsa1 gene identified no variability between the B.
microti Gray Strain ATCC 30221 BmSA1 gene and BmSA1 genes from other B. microti
isolates identified and registered to piroplasmaDB.org (Table 3). Thus, both BmSA1 and
BMN1-21 proteins are well conserved between the B. microti parasite isolates that have
been sequenced to date.
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a)

b)

Figure 5: a) Image of the NCBI local alignment tool results aligning the bmn1-9 gene
from B. microti MN1 strain (Query) against the bmsa1 gene from B. microti Gray Strain
(Subject). The two sequences share 99.86% identity starting at subject position 27, and
query position 1. An adenine at query position 374 is replaced with a guanine in the
subject. b) An alignment of the protein translated from the bmn1-9 gene and the bmsa1
gene. There is one amino acid difference between the two proteins, a lysine in BMN1-9
position 124 is replaced with an arginine in BmSA1 position 133. Local alignment was
performed using the Smith-Waterman algorithm.
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Since we confirmed that the BmSA1 and BMN1-21 proteins were conserved between
the B. microti Gray strain and other known isolates of B. microti, the B. microti Gray strain
was used as a template for amplification of both bmsa1 and BMN1-21 to clone each gene
into the PichiaPink™ heterologous expression system to create recombinant protein.
Previous studies in our lab confirmed that both the bmsa1 and bmn1-21 genes encode a
single exon that codes for the expression of the entire proteins. Figure 2 shows a diagram
of the process followed for the expression of the BmSA1 and BMN1-21 as heterologous
proteins in the PichiaPink yeast protein expression system:1. Clone the genes of interest
(GOIs) in frame into pPinkα-HC expression vectors; 2. Linearize the pPinkα-HC
expression vectors encoding the GOIs and introduce it into the PichiaPink™ yeast strains
by electroporation, and plate and select transformants on selection media, and; 3. Conduct
small scale pilot expression studies of BmSA1 and BMN1-21 proteins to ensure
production of the heterologous protein.
1. Cloning Genes of Interest (GOIs) Into pPinkα-HC Secretion Vector
The pPinkα-HC vector is intricately designed to enable cloning and expression of
heterologous protein for secretion by PichiaPink™ yeast strains following induction of
protein expression using methanol. A diagram of the pPinkα-HC vector for secreted
proteins is shown in figure 6a. The protein-coding DNA for bmsa11 and bmn1-21 were
inserted downstream of the methanol-induced AOX1 promoter site in the pPinkα-HC
vector. Downstream of the AOX1 promoter site is the Saccharomyces cerevisiae α-mating
factor secretion signal harboring the AOX1 native Kozak start signal with an ATG start
site. Immediately downstream of and in-frame with the α-mating factor secretion signal is
where the GOIs are inserted for proper transcription and protein expression and secretion.
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a)

b)
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c)

Figure 6. a) Detailed sequence map of the PichiaPink Vector for secreted proteins with all
vector genes and regulator regions labeled, before GOI insertion. b) Simplified sequence
map showing restriction digest schematic for cloning preparation. c) Actual sequence with
codons, shows features around cloning site with restriction sites. The “multiple cloning
site” is the region in between the StuI restriction digestion site and the beginning of the
CYC1 transcription termination region. It contains KpnI, Nae1, and Swa1 restriction sites
(Invitrogen, 2014).
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The diagram in figure 6b shows the cloning site in the pPinkα-HC vector where the
GOIs are directionally cloned into the vector. As shown in figure 6b, the pPinkα-HC vector
is specifically designed with a StuI restriction site directly following the α-mating factor
secretion signal. Restriction digest with StuI creates a 5’ blunt end cleavage at the exact
site where the GOIs need to be inserted. This creates a convenient mechanism for
generating an insertion/ligation site for GOI insertion. Downstream of the StuI site there is
a “multiple cloning site” harboring several restriction enzyme cleavage sites, including a
KpnI site which we used to generate a 3’ overhang end. The purpose of this double
digestion with one blunt end and one overhang end is to create non-identical insertion sites
on the vector plasmid that ensure proper orientation of our GOIs during the
insertion/ligation cloning reaction (Figure 6b, 6c).
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Specialized primers were created to amplify the GOIs by PCR in order to create
compatible ends on our GOIs for insertion into the vector. This meant that when bmsa1
and bmn1-21 genes were amplified by PCR from B. microti Gray strain (ATCC 30221),
PCR primers were designed to include adapters containing the correct restriction enzyme
sites to create GOIs compatible with the StuI/KpnI sites on the vector. For bmn1-21, a MlyI
restriction site adapter was added to the 5’ end, creating a compatible blunt end with the
one created on the vector, and a KpnI restriction site adapter was added to the 3’ end,
creating a compatible overhang end with the one created on the vector following restriction
enzyme digestion (Figure 7a) (Table 1). Unfortunately, the same technique could not be
used when amplifying the BmSA1 gene because bmsa1 contains an internal MlyI restriction
site, and cleavage with this enzyme would have destroyed the bmsa1 gene. As an
alternative, we created a 5’ phosphorylated primer with no restriction site for amplifying
bmsa1. This modification created the same compatible 5’ phosphorylated blunt end needed
for insertion of the gene in the cloning vector. The 3’ PCR primer for the amplification of
bmsa1 was designed with a KpnI restriction site adapter to create compatible overhang
ends with the vector, the same as with bmn1-21 (Figure 7b) (Table 1).
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a)

b)

Figure 7. The adaptors were added to the 5’ and 3’ PCR primers to create GOIs
compatible for cloning into the vector. a) The 5’ and 3’ end adapters of the bmn1-21 gene
after the addition of a 5’ MlyI site adapter and a 3’ KpnI site adapter. b) The 3’ end of the
bmsa1 gene after the addition of a 3’ KpnI site adapter.
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The bmsa1 and bmn1-21 genes were successfully amplified by PCR from B. microti
Gray strain (ATCC 30221) using the primers described above to amplify the coding region
of the gene along with the added 5’ and 3’ additional adaptors for cloning into the
PichiaPink vector. The wild-type bmsa1 gene contains a 78 base pair secretion signal. The
PCR primers amplified the bmsa1 gene immediately downstream of the secretion signal
because the secretion of GOIs secretion signals is directed with the Saccharomyces
cerevisiae α-mating factor secretion signal in the vector to drive secretion of the cloned
protein in yeast strains as previously described. The wild-type bmn1-21 gene contains a 69
base pair secretion signal which was excluded in the amplification process for the same
reason. A proof-reading enzyme (Phusion® High-Fidelity PCR Master Mix) was used for
PCR amplification of both bmsa1 and bmn1-21 to avoid the introduction of errors during
gene amplification that might impact expression of the full-length protein. Shown in Figure
8 are the PCR products for the amplified GOIs with the modified 5’ and 3’ end adapters to
incorporate required restriction enzyme sites. The PCR product was visualized through
horizontal agarose gel electrophoresis. bmsa1 (909 base pairs) is shown in lane 2, and
bmn1-21 (846 base pairs) is shown in lane 3. The 1kb plus Invitrogen TrackIt™ ladder is
shown in lane 1 as a comparison in order to estimate the size of the PCR products.
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Figure 8: Horizontal gel electrophoresis of the bmsa1 and bmn1-21 amplified DNA with
the included 5’ and 3’ adaptors. Lane 1 is a 1kb plus Invitrogen TrackIt™ ladder with the
1kb standard band labeled. Lane 2 shows a band consistent with the 909-base pair (bp)
bmsa1 gene segment expected to be yield from PCR gene amplification. Lane 3 shows a
band consistent with the 846-base pair bmn1-21 gene segment expected to be yield from
PCR gene amplification
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The pPinkα-HC vector and GOIs were digested with the appropriate restriction
enzymes for directional cloning of the GOIs into the vector, the digested products purified,
and pPinkα-HC vector/GOI duplexes were created by the addition of ligase enzyme. The
pPinkα-HC vector/GOI duplexes were used to transform the newly formed DNA duplexes
into E. coli for propagation and selection. The pPinkα-HC vector includes an ampicillin
resistance gene under the control of its own promoter for the selection of the transformants
in E. coli. This resistance cassette also provides the selection with carbenicillin which we
used for selection.
Transformed E. coli was grown overnight at 37°C on LB agar plates containing
carbenicillin. Thirteen colonies were selected from LB agar plates containing E. coli
transformed with BmSA1 construct for validation that the plasmid in each E. coli colony
contained the correct BmSA1 insert. DNA was isolated from each bacterial colony and
PCR performed with primers 5’ and 3’ to the GOI insertion site in the vector to amplify the
gene insert if present. The sequence of “Vector-specific primers” used for PCR
amplification to identify insertion of the GOIs are shown in Table 1. As shown in the
horizontal electrophoresis gel in figure 9a, five of the 13 colonies screened by
electrophoresis were positive for the insertion of a genomic sequence of roughly 1kb, the
expected size for the BmSA1 in the GOI insertion site for the vector (Figure 9a). This
means the other 8 colonies that grew on the selection plates did not include the insertion of
a gene even though they were resistant to carbenicillin. The plasmid was purified from the
bacterial colonies that had an insertion of the correct size in the insertion site of the vector.
The plasmid DNA was sequenced using sanger sequencing in separate reactions with either
the 5’ or 3’ primers that spanned the insertion site in the vector in order to sequence the
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b)
a)
Figure 1

c)

Figure 9: a) Horizontal gel electrophoresis of LB + Carbenicillin selected E. coli for
validation of vector insertion. DNA was isolated from colonies using a boil preparation
procedure. All DNA samples were loaded with 8µl of DNA in 2µl of TrackIt™
Cyan/Yellow loading buffer. Lane 1 is a 1kB plus TrackIt™ ladder with the 1kB standard
band labeled (to the left). Colony 1 is shown in lane 3, colony 2 is shown in lane 7, colony
3 is shown in lane 8, colony 4 is shown in lane 9, and colony 5 is shown in lane 14. b)
Sanger sequencing results of colonies 1-5 aligned with the pPink-α HC vector/bmsa1
duplex using the bmsa1 reference sequence on piroplasmaDB.com for B. microti strain RI
as the query. Sequencing was performed using both the forward and reverse vector-specific
primers for sequencing. The forward vector-specific primer is shown for in the second row
to the bottom. The bottom row shows the vector/bmsa1 junction, which is the last 2 codons
of the vector followed by the first 2 codons of the bmsa1 protein-coding gene. The
beginning of the bmsa1 protein-coding gene is denoted by the black line and green arrow.
c) The chromatograph of the colony 2 forward primer sequence at the vector/bmsa1
junction. The N at position 20 correlates to the N at position 1998 in Figure 9b. All
alignments were performed using Cluastal Omega alignment program through Snap
Gene® software.
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inserted GOI. The DNA sequence obtained through Sanger sequencing was examined to
ensure that the bmsa1 sequence of the inserted GOI did not contain mutations introduced
by PCR amplification and that the sequence was in frame with the pPink-α HC plasmid.
Figure 9b shows the alignment of bmsa1 sequenced from each of the positive plasmids
using both forward and reverse primers for sequencing. The Sanger sequencing showed
that the sequence was correct for the bmsa1 gene with the exception that the bmsa1
junctional sequence between the pPink-α HC vector and bmsa1 start site in the sequencing
chromatograph was unclear (Figure 9c). New primers were designed specifically to
amplify the junctional region between the bmsa1 coding region and the pPink-α HC vector
(Table 1). In the meantime, plasmid number 2 (Figure 9a, 9b, 9c) was selected for
electroporation into the PichiaPink™ yeast strains 1-4.
Twenty-two colonies were selected from LB agar plates containing E. coli transformed
with the bmn1-21 gene for validation of the correct gene insert. DNA was isolated from
each bacterial colony and PCR performed with primers 5’ and 3’ to the GOI insertion site
in the vector to amplify the GOI if present. “Vector-specific primers” from Table 1 were
used for identifying the bmn1-21 insert as described for the bmsa1 colonies. Eight of the
22 colonies screened by electrophoresis were positive for the presence of a genomic
sequence of approximately 1kb inserted into the insertion site in the vector (Figure 10).
The plasmid DNA from each of the eight bacterial colonies that showed the presence of an
insert of the correct size were sequenced using sanger sequencing in separate reactions
with either the 5’ or 3’ primers that spanned the insertion site in the vector in order to
sequence the inserted GOI. Sanger sequencing was not effective for the bmn1-21 plasmid
eight due to lack of priming during sequencing. bmn1-21 plasmid 4 had multiple mutations
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throughout with no insertions or deletions. The other six bmn1-21 plasmids all contained
the same sequence which differed by a few silent mutations from the B. microti BMN
strain bmn1-21 sequence published on PiroplasmaDB (Figure 11). Because the sequence
homology was consistent between each of the bmn1-21 plasmids the sequence was
believed to be accurate for the bmn1-21 sequence from the Gray Strain of B. microti that
was used. The six E. coli clones with a plasmid containing the correct in-frame sequence of
bmn1-21 were frozen down in glycerol stock for future studies. At this point, the decision
was made to not immediately transform Pichia pastoris strains with bmn1-21 as the first
priority was the creation of recombinant bmsa1 for use with a pilot BmSA1 antigen
specific ELISA under development.
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Figure 10: Horizontal gel electrophoresis of LB + Carbenicillin selected E. coli for
validation of Vector/bmn1-21 DNA insertion. DNA was isolated form colonies using a boil
preparation procedure. All DNA samples were loaded with 8µl of DNA mixed with 2µl of
TrackIt™ Cyan/Yellow loading buffer.
Lane 1 and 13: a 1kb plus TrackIt™ ladder with the 1kb standard band labeled (to the left).
Lane 7: Insert from bacterial colony termed “Colony 1”
Lane 9: Insert from bacterial colony termed “Colony 2”
Lane 10: Insert from bacterial colony termed “Colony 3”
Lane 14: Insert from bacterial colony termed “Colony 4”
Lane 16: Insert from bacterial colony termed “Colony 5”
Lane 20: Insert from bacterial colony termed “Colony 6”
Lane 21: Insert from bacterial colony termed “Colony 7”
Lane 24: Insert from bacterial colony termed “Colony 8”
*all other lanes contained colonies screened that were negative for presence of
Vector/bmn1-21 insert by PCR product visualized through horizontal gel electrophoresis.
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Figure 11: Sanger sequencing results of colonies 1-8 aligned with the pPink-α HC
vector/bmn1-21 duplex using the bmn1-21 reference sequence on piroplasmaDB.com for
B. microti strain RI as the query. Sequencing was performed using both the forward and
reverse vector-specific primers for sequencing. The forward vector-specific primer is
shown for in the second row to the bottom. The bottom row shows the vector/bmn1-21
junction, which is the last 2 codons of the vector followed by the first 2 codons of the
bmn1-21 protein-coding gene. The beginning of the BmSA1 protein-coding gene is
denoted by the black line and green arrow.

49

2) Electroporation of PichiaPink™ strains with linearized plasmid DNA
The BmSA1 expressing pPinkα-HC vector was linearized by restriction enzyme
digestion within the TRP2 gene of the vector. TRP2 encodes a metabolic enzyme in the
PichiaPink™, and integration of linearized vector can only occur at the TRP2 locus of
PichiaPink™ strains. The restriction enzyme EcoN1 was used to linearize the bmsa1
expressing pPinkα-HC vector within the TRP2 gene (Figure 6a). Following restriction
enzyme digestion to linearize bmsa1 expressing pPinkα-HC vector, the linearized plasmid
was compared to uncut plasmid through horizontal gel electrophoresis verifying
linearization of the plasmid. Electrophoresis validated that the restriction enzyme digestion
resulted in linearization of the plasmid as the linearized product ran slower than the
supercoiled non-linearized plasmid (data not shown).
Electroporation was conducted in 2mm electroporation cuvettes under the
following electroporation conditions: 25µF, 200Ω, 150v, with readouts of between 1452V1475V, all of a duration of 5 milliseconds or less. After electroporation, PichiaPink™ cells
were gently resuspended in YPDS, allowed to recover for 2 hours, then replated on PAD
selection plates for selection.
3) Isolation of Transfected PichiaPink™ Strains
Purified linearized bmsa1 expression pPinkα-HC vector duplex was introduced into
four different PichiPink™ strains by electroporation. Transfected PichiaPink™ yeast
colonies were selected using adenine deficient selection plates. Prior to transfection
PichiaPink™ yeast are ADE2 deficient. ADE2 encodes phosphoribosylaminoimidazole
carboxylase, a necessary enzyme in the biosynthesis of purine nucleotides (jones and fink,
1992). Additionally, ADE2 mutants are adenine auxotrophs and cannot grow on adenine
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deficient media. Shown on Figure 6 is the ADE2 gene under the control of its own 13 base
pair promoter inside pPinkα-HC vector. As a result, only successfully transfected yeast
containing the linearized pPinkα-HC vector/bmsa1 duplex can grow on adenine deficient
selection plates. In addition to being adenine auxotrophs, ADE2 mutants will accumulate
purine precursors in vacuoles when the gene is under expressed, causing colonies to
display a red color. This creates a second quantitative level of expression to evaluate
transfected colonies. Only colonies that have taken up the vector genome will be able to
grow on adenine deficient plates, but colonies that have only taken up a low copy number
of the vector will under-express the ADE2 gene, displaying a red color colony instead of a
white color colony. This is why it was important to select for only white colonies during
the plate selection. If colonies contain higher copy levels of the bmsa1 gene, then
theoretically they should express higher levels of protein under methanol induction.
All four yeast strains (that differ in the number of endogenous protease genes they
contain) were transfected with the bmsa1 containing vector by electroporation and plated
on PAD selection plates. However, only strains 1 and 2 formed any colonies on the PAD
selection plates. The strain 1 culture contained 3 white colonies, while the strain 2 culture
contained 2 white colonies. These colonies were expanded on fresh PAD selection plates
where they were used to generate glycerol stocks and inoculate starter cultures for pilot
expression studies of rBmSA1 protein as well as for the creation of glycerol stocks of the
transfected yeast colonies for long-term storage.
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4) Pilot Expression Studies of Heterologous BmSA1 Protein Expression
As mentioned previously, expression of the cloned bmsa1 gene was designed to fall
under the control of a methanol induced AOX1 promoter in the yeast PichiaPink™ vector.
Another consideration for expression of heterologous proteins in PichiaPink™ yeast strains
are the use of four different strains that differ in the number of protease genes that have
been deleted in each yeast. While Pichia pastoris yeast generally secrete very low levels of
native proteins, they have been reported to secrete proteases into expression media,
particularly during fermentation. While this study was designed to express proteins under
aerobic conditions, protease secretion and possible degradation of BmSA1 was still taken
into consideration. PichiaPink™ strain 1 is the “protease wild-type” that has no genetic
alteration to any endogenous protease genes. PichiaPink™ strain 2 is a pep4 knockout. The
pep4 gene encodes proteinase A. This proteinase is a vacuolar, self-activating aspartyl
protease, that is also involved in activating other proteases. Out of an abundance of
caution, all samples were harvested in the presence of HALT™ protease inhibitors to
prevent any degradation of secreted rBmSA1 protein during the pilot expression studies.
Yeast Culture to Induce Protein Expression
To examine heterologous expression of the BmSA1 protein, transfected
PichiaPink™ strains 1 and 2 were first cultured in a BMGY to generate a starter culture of
PichiaPink™ yeast cells in the absence of methanol. Cells were grown for 24 hours in a
shaking incubator (280rpm) at 28°C. After 24 hours, cells were harvested and centrifuged
at 1,500 x g for 5 minutes. The BMGY media was decanted and the cell pellet was
resuspended in 2mL of BMMY. The methanol in the BMMY medium induces expression
of the heterologous cloned recombinant protein by PichiaPink™ strains. The BMMY
52

cultures were grown in a shaking incubator (280rpm) at 28°C for 24-hours before the first
time point collection. 100µl of culture was collected for each time point, and cultures were
replenished with 40% methanol after each time point collection. Depending on the study,
24-hour, 30-hour, 48-hours, 72-hour, and 96-hour time points were collected.
SDS-PAGE Coomassie Staining:
An SDS-PAGE Coomassie stain is used to determine relative concentrations of
protein in a sample separated by size. Samples from yeast cultures were examined by SDSPAGE gel run under reducing conditions after heating the samples at 100°C for ten
minutes in loading dye that contained 2-mercaptoethanol (2ME).
Protein expression by the PichiaPink yeast was first examined by SDS-PAGE
followed by Coomassie staining to detect proteins on the gel. Supernatant from the
PichiaPink™ cultures was first examined to evaluate whether a protein of the correct size
was induced by methanol and secreted by the yeast into the supernatant. The yeast pellet
was also examined to determine if the BmSA1 protein was secreted or retained within the
yeast cell. Samples were collected at 24-hour, 48-hour, 72-hours, and 96-hour increments
for supernatant samples. For the cell pellet lysate, samples were collected at 24-hour, 48hour, and 72-hour increments. Gels were stained with Coomassie stain to evaluate the
relative production of secreted proteins, as well as the production and secretion of a protein
that is the same size of BmSA1 protein. Gels were loaded with 20µl of protein sample.
Coomassie stain showed several protein bands in the yeast supernatant, one protein of
approximately 40kDa in size was the approximately correct size for BmSA1, which is 35
kDa in size (Figure 12 and Figure 13). This protein band appeared in both the supernatant
and cell pellet lysate (Figure 12, Figure 13, and Figure 14 ). In the supernatant, this band
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was present at low amounts at the 24-hour time point compared to 48-hour time point
collections (Figure 12). The protein bands were even more robust after 72 hours, compared
to the 48-hour collections. (Figure 13). In the cell pellet lysate samples, protein
concentration was relatively equal between 24- and 48-hour samples as shown by the equal
band robustness between the two time points in Figure 13. The expression of a protein
band approximately the size of BmSA1 in the supernatant with relatively low expression of
other secreted proteins was encouraging because it suggests the BmSA1 protein was being
expressed by the PichiaPink™ yeast and was in the secreted fraction which would be
helpful for purification of the protein.
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Figure 12: SDS-PAGE gel electrophoresis Coomassie stain of supernatant from methanol
induced PichiaPink™ cultures. All lanes were loaded with 20µl of sample.
Lane 1: Precision Plus Protein™ Standard.
Lane 2: Strain 1 Colony 1 culture supernatant, 24 hours post-induction.
Lane 3: Strain 1 Colony 1 culture supernatant, 48 hours post-induction.
Lane 4: Strain 1 Colony 2 culture supernatant, 24 hours post-induction.
Lane 5: Strain 1 Colony 2 culture supernatant, 48 hours post-induction.
Lane 6: Strain 1 Colony 3 culture supernatant, 24 hours post-induction.
Lane 7: Strain 1 Colony 3 culture supernatant, 48 hours post-induction.
Lane 8: Strain 2 Colony 1 culture supernatant, 24 hours post-induction.
Lane 9: Strain 2 Colony 1 culture supernatant, 48 hours post-induction.
Lane 10: Strain 2 Colony 2 culture supernatant, 24 hours post-induction.
Lane 11: Strain 2 Colony 2 culture supernatant, 48 hours post-induction.
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Figure 13: SDS-PAGE gel electrophoresis Coomassie stain of supernatant from methanol
induced PichiaPink™ cultures. All lanes were loaded with 20µl of sample.
Lane 1: Precision Plus Protein™ Standard.
Lane 2: Strain 1 Colony 1 culture supernatant, 48 hours post-induction.
Lane 3: Strain 1 Colony 1 culture supernatant, 72 hours post-induction.
Lane 4: Strain 1 Colony 2 culture supernatant, 48 hours post-induction.
Lane 5: Strain 1 Colony 2 culture supernatant, 72 hours post-induction.
Lane 6: Strain 1 Colony 3 culture supernatant, 48 hours post-induction.
Lane 7: Strain 1 Colony 3 culture supernatant, 72 hours post-induction.
Lane 8: Strain 2 Colony 1 culture supernatant, 48 hours post-induction.
Lane 9: Strain 2 Colony 1 culture supernatant, 72 hours post-induction.
Lane 10: Strain 2 Colony 2 culture supernatant, 48 hours post-induction.
Lane 11: Strain 2 Colony 2 culture supernatant, 72 hours post-induction.
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Figure 14: SDS-PAGE gel electrophoresis Coomassie stain of cell pellet lysate from
methanol induced PichiaPink™ cultures. All lanes were loaded with 20µl of sample.
Lane 1: Strain 1 Colony 1 cell lysate, 24 hours post-induction.
Lane 2: Strain 1 Colony 1 cell lysate, 48 hours post-induction.
Lane 3: Strain 1 Colony 2 cell lysate, 24 hours post-induction.
Lane 4: Strain 1 Colony 2 cell lysate, 48 hours post-induction.
Lane 5: Strain 1 Colony 3 cell lysate, 24 hours post-induction.
Lane 6: Strain 1 Colony 3 cell lysate, 48 hours post-induction.
Lane 7: Precision Plus Protein™ Standard.
Lane 8: Strain 2 Colony 1 cell lysate, 24 hours post-induction.
Lane 9: Strain 2 Colony 1 cell lysate, 48 hours post-induction.
Lane 10: Strain 2 Colony 2 cell lysate, 24 hours post-induction.
Lane 11: Strain 2 Colony 2 cell lysate, 48 hours post-induction.
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Western Blot Analysis:
To confirm that the secreted 40kDa protein was rBmSA1, western blot with BmSA1
specific antibodies were used to evaluate the protein in PichiaPink™ supernatants.
Supernatants were probed by Western Blot analysis with the hybridoma antibodies RD167
and RD261 because of their previous validation against E. coli expressed rBmSA1, as
previously described. Both antibodies recognized the protein of approximately 40kDa
consistent with the size of BmSA1, and consistent with the SDS-PAGE Coomassie stain
results (Figure 15, and Figure 16). It was immediately apparent that the antibodies were
recognizing proteins of other sizes as well. The RD167 antibody also stained a protein of
approximately 70kDa, and another of approximately 30kDa (Figure 15). However, this
was consistent with the previous validation of RD167 against E. coli expressed rBmSA1,
which also showed that RD167 recognized larger molecular weight protein bands as well.
The RD261 antibody recognized a protein of approximately 70kDa as well (Figure 16).
While the recognition of protein bands with sizes not consistent with BmSA1 was
established for RD167 in previous validation studies, the recognition of protein bands with
sizes not consistent with BmSA1 by RD261 was not consistent with previous validation
studies. Even more unusual was that these bands appeared more robust than the 40kDa
rBmSA1 band itself (Figure 15 and Figure 16). Because of this, we decided to repeat the
western blot assays in the presence of a B. microti lysate as a positive control, to more
accurately compare the size of the protein bands that the antibodies recognized in the B.
microti parasite lysate compared to the size of the protein bands secreted by the transfected
PichiaPink™ yeast. In theory, it was possible that the 70kDa protein was a BmSA1 dimer
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and the 30kDa product a degradation product form BmSA1 that still contained the BmSA1
epitope recognized by the antibodies to BmSA1.
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RD167

Figure 15: Western Blot analysis of supernatant samples of methanol induced PichiaPink
™. This membrane was probed with mAb RD167 (1:10). To detect mAbs, blots were
incubated with 2° antibody, goat anti-mouse IgG (1:10,000). The Arrow is pointing to the
BmSA1 protein detected in the B. microti cell lysate.
Lane 1: Precision Plus Protein™ Standard.
Lane 2: Strain 1 Colony 1 culture supernatant, 24 hours post-induction (20µl).
Lane 3: Strain 1 Colony 1 culture supernatant, 48 hours post-induction (10µl).
Lane 4: Strain 1 Colony 1 culture supernatant, 72 hours post-induction (10µl).
Lane 5: Strain 1 Colony 1 culture supernatant, 96 hours post-induction (10µl).
Lane 6: Strain 2 Colony 1 culture supernatant, 24 hours post-induction (10µl).
Lane 7: Strain 2 Colony 1 culture supernatant, 48 hours post-induction (10µl).
Lane 8: Strain 2 Colony 1 culture supernatant, 72 hours post-induction (10µl).
Lane 9: Strain 2 Colony 1 culture supernatant, 96 hours post-induction (10µl).
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RD261

Figure 16: Western Blot analysis of supernatant samples of methanol induced PichiaPink
™. This membrane was probed with mAb RD621 (1:10). To detect mAbs, blots were
incubated with 2° antibody, goat anti-mouse IgG (1:10,000). The Arrow is pointing to the
BmSA1 protein detected in the B. microti cell lysate. All lanes were loaded with 10µl of
sample.
Lane 1: Precision Plus Protein™ Standard.
Lane 2: Strain 1 Colony 1 culture supernatant, 24 hours post-induction.
Lane 3: Strain 1 Colony 1 culture supernatant, 48 hours post-induction.
Lane 4: Strain 1 Colony 1 culture supernatant, 72 hours post-induction.
Lane 5: Strain 1 Colony 1 culture supernatant, 96 hours post-induction.
Lane 6: Strain 2 Colony 1 culture supernatant, 24 hours post-induction.
Lane 7: Strain 2 Colony 1 culture supernatant, 48 hours post-induction.
Lane 8: Strain 2 Colony 1 culture supernatant, 72 hours post-induction.
Lane 9: Strain 2 Colony 1 culture supernatant, 96 hours post-induction.
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Results from the repeat western blot analyses with B. microti lysate control showed
that both of these antibodies did recognize protein bands of various sizes, including the
70kDa and 30kDa bands recognized in the PichiaPink™ supernatant (Figure 17 and Figure
18). Another observation from these repeat western blot analyses was the size of the B.
microti lysate BmSA1 protein band; the size of the B. microti lysate BmSA1 was slightly
smaller than the PichiaPink™ rBmSA1 (Figure 18). The 70kDa and 30kDa protein bands
could be endogenous PichiaPink™ secreted proteins, since we had not cloned any B.
microti genes into the yeast other than the 35kDa rBmSA1. Since it was apparent that the
antibodies were recognizing some endogenous PichiaPink™ proteins, we wanted to test
these antibodies against non-transfected vector negative PichiaPink™ strains’ supernatants
collected under the same induction conditions.
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RD167

Figure 17: Western Blot analysis of supernatant samples of methanol induced PichiaPink
™. This membrane was probed with mAb RD167 (1:10). To detect mAbs, blots were
incubated with 2° antibody, goat anti-mouse IgG (1:10,000). The Arrow is pointing to the
BmSA1 protein detected in the B. microti cell lysate.
Lane 1: Precision Plus Protein™ Standard.
Lane 2: Strain 1 Colony 1 culture supernatant, 24 hours post-induction (20µl)
Lane 3: Strain 1 Colony 1 culture supernatant, 48 hours post-induction (10µl)
Lane 4: Strain 1 Colony 1 culture supernatant, 72 hours post-induction (10µl)
Lane 5: Strain 1 Colony 1 culture supernatant, 96 hours post-induction (10µl)
Lane 6: Strain 2 Colony 1 culture supernatant, 24 hours post-induction (20µl)
Lane 7: Strain 2 Colony 1 culture supernatant, 48 hours post-induction (10µl)
Lane 8: Strain 2 Colony 1 culture supernatant, 72 hours post-induction (10µl)
Lane 9: Strain 2 Colony 1 culture supernatant, 96 hours post-induction (10µl)
Lane 10: B. microti Gray Strain ATCC 30221 cell lysate.
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RD261

Figure 18: Western Blot analysis of supernatant samples of methanol induced PichiaPink
™. This membrane was probed with mAb RD621 (1:10). To detect mAbs, blots were
incubated with 2° antibody, goat anti-mouse IgG (1:10,000). The Arrow is pointing to the
BmSA1 protein detected in the B. microti cell lysate.
Lane 1: Precision Plus Protein™ Standard.
Lane 2: Strain 1 Colony 1 culture supernatant, 24 hours post-induction
Lane 3: Strain 1 Colony 1 culture supernatant, 48 hours post-induction
Lane 4: Strain 1 Colony 1 culture supernatant, 72 hours post-induction
Lane 5: Strain 1 Colony 1 culture supernatant, 96 hours post-induction
Lane 6: Strain 2 Colony 1 culture supernatant, 24 hours post-induction
Lane 7: Strain 2 Colony 1 culture supernatant, 48 hours post-induction
Lane 8: Strain 2 Colony 1 culture supernatant, 72 hours post-induction
Lane 9: Strain 2 Colony 1 culture supernatant, 96 hours post-induction
Lane 10: B. microti Gray Strain ATCC 30221 cell lysate.
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There was concern that the identified protein in the PichiaPink™ supernatant was
not strongly induced by methanol and that the monoclonal antibodies did not provide
strong signals for the protein in western blots. In order to evaluate whether the 40kDa
protein in the PichiaPink™ supernatant was a yeast protein instead of BmSA1, Western
Blot analysis was performed using PichiaPink yeast that had not been transfected. Nontransfected vector negative PichiaPink™ strains’ supernatants were collected under the
same induction conditions as transfected PichiaPink™ yeast.
Western Blot analysis with antibody RD261 comparing transfected PichiaPink™
yeast to control non-transfected yeast showed that this antibody recognized a protein of the
same size as the PichiaPink™ rBmSA1 in the non-transfected vector negative
PichiaPink™ strains’ supernatants (Figure 19). Based on the fact that BmSA1 protein did
not seem to be expressed in yeast, DNA was isolated from transfected yeast and primers
were used to amplify the vector bmsa1 insert by PCR to re-evaluate the DNA sequence and
to confirm that the bmsa1 gene was cloned in frame with the vector. The PCR product was
sequenced using Sanger sequencing with primers 5’ and 3’ to the vector that spanned the
insertion site. New primers were designed to the bmsa1 insert in order to sequence the
junction site (Table 1, “bmsa1 interior primers”). Sequencing with these primers revealed
that there was a 4 base pair deletion mutation starting at the +2 position of the bmsa1 gene
coding region (Figure 20). This mutation altered the entire amino acid sequence of the
translated protein and resulted in a protein sequence that was out of frame. This setback
revealed that the 40kDa protein band observed by SDS-PAGE Coomassie stain and
Western Blot analysis was not rBmSA1, which explained the discrepancy in size between
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the 35kDa B. microti lysate BmSA1 and the 40kDa protein recognized by the RD167 and
RD261 antibodies.
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RD167

Figure 19: Western Blot analysis of supernatant samples of methanol induced PichiaPink
™. This membrane was probed with mAb RD261 (1:10). To detect mAbs, blots were
incubated with 2° antibody, goat anti-mouse IgG (1:10,000). The Arrow is pointing to the
BmSA1 protein detected in the B. microti cell lysate. All lanes were loaded with 10µl of
sample.
Lane 1: Precision Plus Protein™ Standard.
Lane 2: Strain 1 Colony 1 culture supernatant, 24 hours post-induction.
Lane 3: Strain 1 Colony 1 culture supernatant, 48 hours post-induction.
Lane 4: Strain 1 Colony 1 culture supernatant, 72 hours post-induction.
Lane 5: Strain 2 Colony 1 culture supernatant, 24 hours post-induction.
Lane 6: Strain 2 Colony 1 culture supernatant, 48 hours post-induction.
Lane 7: Strain 2 Colony 1 culture supernatant, 72 hours post-induction.
Lane 8: Vector negative PichiaPink™ (negative control) supernatant, 24 hours postinduction
Lane 9: Vector negative PichiaPink™ (negative control) supernatant, 48 hours postinduction
Lane 10: Vector negative PichiaPink™ (negative control) supernatant, 72 hours postinduction
Lane 11: B. microti Gray Strain ATCC 30221 cell lysate.
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Figure 20: Saner sequencing from genomic DNA isolated from the transfected
PichiaPink™ and amplified using sequencing primers from Table 1. On the top is the
reverse compliment of the gene sequence returned from Sanger sequencing on the
transfected PichiaPink™ purified vector using the interior reverse primers for sequencing
the 5’ vector/bmsa1 junction. On the bottom is the 5’ strand alignments of the purified
vector and the bmsa1 reference strand. Highlighted in red is the 4 base pair deletion
presents in the purified vector sequence.
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Electroporation of PichiaPink™ with Plasmid Insert 3 bmsa1:
After discovering the transfected PichiaPink™ strains created for this study
contained a deletion mutation that completely altered the identity of the protein being
expressed, it was necessary to generate new PichiaPink™ clones with an in frame bmsa1
gene before conducting any further studies. Sanger sequencing conducted earlier in the
study showed colony 3 (Figure 10a, 10b) could be a good candidate for insertion into the
vector for heterologous protein expression. However, the sequencing results were
imperfect, so plasmids were purified from E. coli with the colony 3 plasmid bmsa1 insert
and sent for Sanger sequencing using the vector-specific primers, as well as the interior
primers designed to capture insertion junctions (Table 1). Figure 21 shows the sequencing
results for this plasmid using all 4 of the aforementioned primers, validating that this
Vector/bmsa1 duplex was in frame and contained 100% sequence identity to the Gray
Strain ATCC 30221 B. microti bmsa1 gene.
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Figure 21: Sequence alignment of the Vector/bmsa1 compared to the Vector/bmsa1
reference sequence. a) Purified Vector/bmsa1 duplex DNA from transfected E. coli colony
3 (Figure 9a,9b) sanger sequencing results aligned with reference Vector/bmsa1 sequence.
All 4 primers for sequencing clones (Table 1) were used for PCR amplification of the
Vector/BmSA1 duplex. The beginning of the BmSA1 protein-coding gene is represented
by the black line and green arrow.
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After validating the sequence of the purified colony 3 DNA Vector/bmsal duplex,
linearization of the plasmid with the restriction enzyme EcoN1 was performed exactly as
described previously, with successful linearization being verified by horizontal gel
electrophoresis (Figure 22). Electroporation of PichiaPink™ strains 1 and 2 was performed
using the linearized plasmid. Selection on PAD selection plates resulted in 2 white
colonies from transfected PichiaPink™ strain1 and 3 white colonies from transfected
PichiaPink™ strain 2. These colonies were expanded on fresh PAD selection plates where
they were used to generate glycerol stocks and inoculate starter cutlers for pilot BmSA1
expression studies. Also, DNA was purified from these expanded colonies for sequence
validation using the vector-specific and bmsa1 interior primers (Table 1) to validate the
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Figure 22: Horizontal gel electrophoresis of the linearized Vector/bmsa1 plasmid duplex
from E. coli colony 3. Plasmid was linearized with the restriction enzyme EcoNI.
Lane 1: The 1 kb plus standard.
Lane 2: The uncut plasmid control
Lanes 3-12: 8 µl aliquots of 1:10 dilutions of restriction digested DNA in sterile water
mixed with 2 µl of TrackIt™ Cyan/Yellow loading buffer, each from separate 20 µl
restriction digest reactions.
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Vector/bmsa1 duplex was in frame and homologues to the Gray Strain ATCC 30221
bmsa1 gene. Sequencing confirmed that the insert in the PichiaPink™ strains was correct,
with the exception of 1 base pair (Figure 23a, 23b). This 1 base pair SNP resulted in an
arginine in the Gray Strain ATCC 30221 BmSA1 amino acid sequence being exchanged
for a threonine (Figure 24).
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a)

b)

Figure 23: a) Sanger sequencing from purified Vector/bmsa1 duplex DNA from
electroporated transfected PichiaPink™ strains. The forward vector-specific primer is
shown for in the second row to the bottom. a) All 5 colonies were sequenced with both
vector-specific forward primers for sequencing clones and interior reverse primers for
sequencing clones 5’ junction. The forward vector-specific primer is shown in the second
row to the bottom. The bottom row shows the vector/bmn1-21 junction, which is the last 2
codons of the vector followed by the first 2 codons of the BMN1-21 protein-coding gene.
The beginning of the BmSA1 protein-coding gene is denoted by the black line and green
arrow) b) Shows the SNP difference between the Vector/bmsa1 reference genome and the
B. microti Gray Strain ATCC 30221 bmsa1 gene.
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Figure 24: An alignment of the protein translated from the bmsa1 gene purified from the
PichiaPink™ clone, and the bmsa1 gene as it appears in the B. microti Gray Strain ATCC
30221. There is 1 amino acid difference between the two proteins, an arginine in the
PichiaPink purified bmsa1 (position 107) is replaced with a threonine in the Gray Strain
ATCC30221 BmSA1. The middle line shows the amino acids that are identical in both
sequences. Local alignment was performed using the Smith-Waterman algorithm
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Western Blot Analysis of PichiaPink™ BmSA1 Insert:
After validating through sequencing that the vector/bmsa1 duplex was integrated
into the PichiaPink™ genome in frame and with sequence homology to the B. microti Gray
Strain ATCC 30221, BmSA1 protein pilot expression studies were initiated. Figure 25
shows the Western Blot analysis of methanol induced PichiaPink™ supernatants at 24hour and 28-hour collection points. One clear protein band of approximately 45kDa was
observed in both strains at the 24-hour time points. At 28 hours, this protein band had
almost completely dissipated. At this point there was no way of validating that the protein
recognized by the antibody RD-261 in this Western Blot analysis was rBmSA1. This
protein could have been the one expressed endogenously by non-transfected PichiaPink™
that was observed in the earlier analyses. Unlike the earlier analysis however, we are
certain that the PichiaPink™ strains used in this later study did contain a pPinkα-HC
vector/bmsa1 duplex that was in frame and homologous to the B. microti Gray Strain
ATCC 30221 bmsa1.
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RD261

Figure 25: Western Blot analysis of supernatant samples of methanol induced PichiaPink
™. This membrane was probed with mAb RD621 (1:10). To detect mAbs, blots were
incubated with 2° antibody, goat anti-mouse IgG (1:10,000). All lanes were loaded with
10µl of sample.
Lane 1: Precision Plus Protein™ Standard.
Lane 2: Strain 1 Colony 1 culture supernatant, 24 hours post-induction.
Lane 3: Strain 2 Colony 1 culture supernatant, 24 hours post-induction.
Lane 4: Strain 1 Colony 1 culture supernatant, 28 hours post-induction.
Lane 5: Strain 2 Colony 1 culture supernatant, 28 hours post-induction.
Lane 6: B. microti Gray Strain ATCC 30221 cell lysate.
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Discussion
The main goal of this study was to generate rBmSA1 that accurately represents that of
the wild-type protein secreted by B. microti. The objective behind this was to validate a
library of hybridoma produced antibodies generated via fusion with B. microti infected
BALB/c mice B-cells and suspected to target BmSA1 proteins according to liquid
chromatography-mass spectrometry (LC-MS/MS) of proteins immunoprecipitated by the
antibodies. Previous studies testing rBmSA1 produced in E. coli against this hybridoma
library generated mixed results. While many BmSA1 antibodies validated by LC-MS/MS
did recognize the E. coli rBmSA1, many did not. There were also antibodies in the
hybridoma library that recognized proteins other than BmSA1 in the E. coli cell lysate.
There was reason to believe that a possible explanation for these discrepancies was the lack
of eukaryotic post-translational modifications altering the specificity of these antibodies
for the rBmSA1 protein produced in E. coli. The goal was to use the heterologously
expressed rBmSA1 in the PichiaPink™ Pichia pastoris expression as a BmSA1 protein
standard for generating an antigen-capture ELISA using the aforementioned antibody
library. It would also be used to identify additional monoclonal antibodies from the mAb
library that specifically targeted BmSA1.
In theory, the expression of rBmSA1 in the PichiaPink™ Pichia pastoris expression
system should address many of the complications that the earlier antibody screening
studies using E. coli expressed rBmSA1 faced. One of those issues was the need to
histidine tag the rBmSA1 and purify it through a nickel column from E. coli cell lysate.
The addition of histidine tags to a protein has the potential to alter the protein’s structure,
function, and/or immunogenicity if the tags cannot be removed (Booth et al., 2018)., which
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was the case with the E. coli rBmSA1 in previous studies. The rBmSA1 protein in E. coli
included both 5’ and 3’ histidine tags and only one of the two tags had the potential to be
removed. The Pichia pastoris expression model allows for proteins to be secreted into the
culture supernatant, eliminating the need for the inclusion of a histidine tag to purify
proteins from cell lysates. Pichia pastoris also secrete very low volumes of proteins
endogenously (Sreekrishna et al., 1997) making it easier to purify heterologous proteins
like rBmSA1 because fewer endogenous proteins have to be removed. Our research
supports this notion, as very little protein was observed through SDS-PAGE Coomassie
staining in the methanol-induced PichiaPink™ culture supernatants (Figure 12 and Figure
13). The ability of Pichia pastoris to secrete proteins into culture without the presence of
many other proteins generates the potential for protein purification by means other than
protein tagging, like ammonium sulfate precipitation, ion-exchange chromatography or
size exclusion chromatography (Shi et al., 2021; Steglich et al., 2020)
Another issue with the E. coli expression model is that E. coli lack posttranslational modification mechanisms present in eukaryotic organisms like B. microti and
Pichia pastoris. We do not know if the lack of post-translational modifications of the E.
coli expressed rBmSA1 was altering the antibody specificity of the rBmSA1, but we do
know that many of the antibodies that had been confirmed as BmSA1 specific by LCMS/MS of immunoprecipitated proteins did not recognize the E. coli expressed rBmSA1.
Research has shown that glycosylated immunogens have their immunogenicity better
conserved when expressed in eukaryotic models compared to prokaryotic models (Bagno
et al., 2020). Since BmSA1 is a glycophosphatidylinositol (GPI) linked protein, it is
reasonable to predict that the structure of E. coli expressed rBmSA1 could have altered
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antibody specificity since E. coli do not have the pathway for synthesizing GPI anchors
(Kinoshita, 2016). Heterologous expression and secretion of recombinant proteins by
Pichia pastoris results in the synthesis of eukaryotic proteins that closely resemble their
native conformation, structure, immunogenicity, and recognition by antibodies
(Balamurugan, et. al).
It is likely that additional studies to optimize the expression of rBmSA1 will
identify optimum induction strategies with methanol for secretion of the heterologous
protein. In this thesis only one study was performed to evaluate the expression of rBmSA1,
and it examined secreted culture media from yeast by Western Blot analysis with mAbs to
BmSA1 for detection. The results were promising as the BmSA1 protein was present in the
transformed yeast culture supernatant. The process for evaluating optimal expression
conditions for rBmSA1 will follow the process that was outlined in the thesis for the outof-frame rBmSA1. Optimization will include performing time-course analysis of rBmSA1
in the yeast culture supernatants and cell lysate before and after methanol induction
followed by an analysis of protein expression by Coomassie staining of total proteins in the
gel and by Western Blot analysis with mAbs confirmed to recognize BmSA1.
In this study, the yeast with pPinkα-HC secretion vector containing the incorrect
bmsa1 gene exhibited poor expression induction after methanol induction. It is also
possible that the yeast with the pPinkα-HC secretion vector containing the correct bmsa1
gene will also exhibit poor expression induction after methanol induction (Figure 12 and
Figure 13). There are several mechanisms that could impair methanol induction of
heterologous proteins in PichiaPink™ yeast. First, the AOX1 promoter is highly repressed
by glucose (Ahmad et al., 2014). The protocol used in these studies to grow a starter
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culture of PichiaPink™ yeast prior to expression involved growing the cultures in BMGY
medium containing glucose. While the cultures were centrifuged, and the BMGY medium
was decanted before the cultures were resuspended in BMMY methanol containing media
for induction, there was no wash step in between to ensure all glucose was absent from the
cell pellets before resuspension in BMMY methanol media. Allowing cultures to grow for
longer durations in the BMMY methanol media might have allowed the yeast to grow to
higher cell densities and given them more time to completely metabolize all of the residual
glucose in the medium to alleviate the AOX1 promoter repression.
There is also evidence to support the possibility that proteolysis could be occurring
inside of the yeast cultures. In figure 25, it is clear that rBmSA1 protein was present at 24
hours and had dissipated by 28 hours. In this study we only successfully transfected
PichiaPink™ strains 1 and 2 with the pPinkα-HC secretion vector/bmsa1 gene duplex.
Strain 1 has no protease knockouts and strain 2 has only one protease knockout which is
the gene pep4 that encodes proteinase A. Both of these strains still have the prb1 gene that
encodes proteinase B. Studies have shown the best way to prevent proteolytic cleavage of
Pichia pastoris heterologously expressed proteins is to clone expression vectors into pep4
prb1 double knockout strains; some have successfully hampered the proteolytic activity of
Pichia pastoris expressed proteases by altering culture conditions in ways like adjusting pH
and temperature of culture conditions, lowering salt concentrations, or adding casamino
acids and increasing peptone concentration of culture mediums (Ahmad et al., 2014; Zhao
et al., 2008).
It is also possible that the PichiaPink™ rBmSA1 is not stable in methanol. The
protocol for sample collection used in these studies involved replenishing induction
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cultures with 100µl of 40% methanol after removing 100µl of sample for protein analysis.
The addition of 100µl of 40% methanol brings the methanol concentration of the BMMY
induction media from 0.5% to 2.475%. Methanol metabolism has been associated with the
degradation of secreted recombinant proteins in Pichia pastoris expression models by
inducing the expression and secretion of vacuolar proteases (Sinha et al., 2005). The
increased methanol concentration between the 24-hour collection and the 28-hour
collection could have triggered the secretion of proteases into the yeast culture and
degraded the rBmSA1 protein. The higher methanol concentration could also be
microbicidal to the yeast, and cell lysis has also been shown to contribute to protease
secretion and degradation of secreted Pichia pastoris recombinant proteins (Sinha et al.,
2005).
The two antibodies RD167 and RD261 had recognized proteins of larger and
smaller molecular weights than BmSA1 in both the previous studies using E. coli
expressed rBmSA1 and in this study (Figure 15 and Figure 16). In the E. coli expressed
rBmSA1 studies the investigators speculated that these bands could have been protein
aggregates (in the case of the 70kDa protein) and protein degradation products (in the case
of the 30kDa protein). Similar-sized proteins were evident in the protein culture samples
from the yeast with pPinkα-HC secretion vector containing incorrect bmsa1 genes,
suggesting that at least in this case, there are endogenous yeast proteins that are secreted
that are approximately 30kDa and 70kDa. It is possible that they represent conserved
proteins in both Pichia pastoris as well as in E. coli.
Considering these new findings, an alternative hypothesis for the identity of the
protein bands recognized by these antibodies could be ubiquitin. Ubiquitin is a 9kDa
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protein that is covalently attached to target proteins as a tagging step in ATP-dependent
protein degradation (Ludemann et al., 1993). Ubiquitin is also one of the few protein
species secreted into the matrix by Pichia pastoris during growth in expression media
(Sreekrishna et al., 1997) If BmSA1 was ubiquinated during hybridoma screening, it is
possible that the antibodies were bound to BmSA1 protein not by one of the protein’s own
epitopes but rather by the ubiquitin that was covalently bound to it. Not only could free
ubiquitin polymers or other ubiquitinated proteins be responsible for the 30kda and 70kDa
protein bands, but a single monoubiquitylation on the rBmSA1 would explain the size
discrepancy of roughly 10kDa difference between the known size of native B. microti
translated BmSA1 (33kDa) and the observed size of rBmSA1 by Western Blot in our study
(Figure 25). This size discrepancy was also observed in the previous work using E. coli
expressed rBmSA1, and while prokaryotes do not have the genes for ubiquitin, they do
encode ubiquitin-like modification proteins that could be cross-reactive to eukaryotic
ubiquitin (Xu et al., 2019). However, one flaw to this hypothesis is that the hybridoma
cells were produced through fusion with B-cells from B. microti infected mice. Like all
mammals, mice express ubiquitin endogenously, and due to self-tolerance, it is unlikely
that they would have produced anti-ubiquitin antibodies. Immunoscreening samples with
anti-ubiquitin antibodies would easily support or reject this hypothesis.
In order for an antigen-capture ELISA to be accurate, the antigens targeted by the
antibodies in the assay need to be well conserved across circulating strains. The BLAST
alignments revealed that the bmsa1 gene is perfectly conserved across all identified B.
microti strains sequenced and uploaded to piroplasmaDB.org (Table 3). This justifies the
continued efforts in synthesizing a reliable, near-native conformation recombinant BmSA1
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for use as a standard in the development of an antigen-capture ELISA. BmSA1 shares
near-perfect gene and amino acid identity with the B. microti BMN1-9 protein, and the
bmn1-9 gene has not been annotated in many of the published B. microti strain genomes
(data not shown). As current B. microti genomic characterization studies have already
begun to re-assign the BMN family of proteins based on biological function and
immunorecognition (Verma et al., 2020), it is possible that BmSA1 and BMN1-9 could
become classified as variants of the same protein. The BMN1-21 protein is also well
conserved, but shares only 23% amino acid sequence identity and 42% sequence similarity
to BmSA1. Because these proteins are both well conserved but not very similar to each
other, BMN1-21 would make a good candidate for the future development of antigen
capture ELISA that might compliment a BmSA1 antigen capture ELISA without
reacting with the BmSA1 antigen.
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